How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences, Inc. (NASDAQ:CLBS) posted its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($1.80) earnings per share for the quarter, topping analysts' consensus estimates of ($1.95) by $0.15. During the same quarter in the previous year, the business earned ($4.35) earnings per share.

When did Caladrius Biosciences' stock split?

Caladrius Biosciences's stock reverse split before market open on Thursday, September 15th 2022. The 1-15 reverse split was announced on Thursday, September 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is David J. Mazzo's approval rating as Caladrius Biosciences' CEO?

1 employees have rated Caladrius Biosciences Chief Executive Officer David J. Mazzo on Glassdoor.com . David J. Mazzo has an approval rating of 100% among the company's employees. This puts David J. Mazzo in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 53.0% of employees surveyed would recommend working at Caladrius Biosciences to a friend.

What other stocks do shareholders of Caladrius Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Caladrius Biosciences investors own include Brainstorm Cell Therapeutics (BCLI) , HubSpot (HUBS) , Karyopharm Therapeutics (KPTI) , OPKO Health (OPK) , Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , Energy Transfer (ET) , Inovio Pharmaceuticals (INO) , AcelRx Pharmaceuticals (ACRX) and CTI BioPharma (CTIC) .

Caladrius Biosciences Stock Price, News & Analysis (NASDAQ:CLBS)

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.43
▼
$8.38
52-Week Range: N/A

Volume: 466,373 shs
Average Volume: 522,308 shs
Market Capitalization: $26.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Caladrius Biosciences Stock (NASDAQ:CLBS)

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

December 1, 2022 | finance.yahoo.com

HARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATION

September 16, 2022 | finanznachrichten.de

Caladrius Biosciences, Inc.: Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

September 15, 2022 | finanznachrichten.de

Caladrius Biosciences, Inc.: Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

September 15, 2022 | finance.yahoo.com

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

September 14, 2022 | seekingalpha.com

CLBS Caladrius Biosciences, Inc.

September 14, 2022 | finance.yahoo.com

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

September 8, 2022 | msn.com

How to get the Protea Caladrius collection in Warframe: Veilbreaker

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

September 8, 2022 | finance.yahoo.com

Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022

August 10, 2022 | finance.yahoo.com

Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer

August 5, 2022 | seekingalpha.com

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript

August 4, 2022 | finance.yahoo.com

Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

August 4, 2022 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates PING, CLBS, MANT

August 3, 2022 | msn.com

Earnings Outlook For Caladrius Biosciences

August 2, 2022 | finance.yahoo.com

Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

July 28, 2022 | finance.yahoo.com

Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time

July 6, 2022 | finance.yahoo.com

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology

June 9, 2022 | finance.yahoo.com

Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group

June 8, 2022 | finance.yahoo.com

Caladrius Biosciences to Present at the BIO International Convention 2022

May 26, 2022 | finance.yahoo.com

Caladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

May 24, 2022 | finance.yahoo.com

Caladrius Biosciences Stops Enrollment In Mid-Stage Heart Disease Study

May 23, 2022 | finance.yahoo.com

Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction

May 19, 2022 | finance.yahoo.com

Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease

May 18, 2022 | finance.yahoo.com

Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference

May 6, 2022 | benzinga.com

CALADRIUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBS

May 6, 2022 | seekingalpha.com

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2022 Results - Earnings Call Transcript

See More Headlines

Receive CLBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caladrius Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 11/30/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Miscellaneous Health & Allied Services
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CLBS
CUSIP: N/A
CIK: 320017
Web: www.caladrius.com
Phone: (908) 842-0100
Fax: 646-514-7787
Employees: 27
Year Founded: 2006

Profitability

EPS (Most Recent Fiscal Year): ($0.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,470,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -27.24%
Return on Assets: -26.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 22.33
Quick Ratio: 22.33

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.54 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 60,583,000
Free Float: 59,250,000
Market Cap: $26.05 million
Optionable: Optionable
Beta: 0.91

Social Links

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. David J. Mazzo B.A. (Hons) (Age 65)
B.Sc. (Hons.), M.Sc., Ph.D., Pres, CEO & Director
Comp: $957.69k
Dr. Kristen K. Buck M.D. (Age 48)
Exec. VP of R&D and Chief Medical Officer
Comp: $825k
Mr. James Nisco
VP of Fin. & Treasury
Mr. Gregory S. Berkin
Chief Information Officer
Mr. John D. Menditto
VP of Investor Relations & Corp. Communications
Eric Powers
Director of Communications and Marketing
Ms. Gail Holler (Age 63)
VP of HR
Dr. Ian Zhang Ph.D. (Age 57)
MBA, Pres of NeoStem (China), Inc and Managing Director of NeoStem (China), Inc
Dr. William K. Sietsema Ph.D. (Age 66)
VP of Global Regulatory Affairs

Key Competitors

View All Competitors

CLBS Stock Analysis - Frequently Asked Questions

How were Caladrius Biosciences' earnings last quarter?: Caladrius Biosciences, Inc. (NASDAQ:CLBS) posted its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($1.80) earnings per share for the quarter, topping analysts' consensus estimates of ($1.95) by $0.15. During the same quarter in the previous year, the business earned ($4.35) earnings per share.
When did Caladrius Biosciences' stock split?: Caladrius Biosciences's stock reverse split before market open on Thursday, September 15th 2022. The 1-15 reverse split was announced on Thursday, September 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What is David J. Mazzo's approval rating as Caladrius Biosciences' CEO?: 1 employees have rated Caladrius Biosciences Chief Executive Officer David J. Mazzo on Glassdoor.com. David J. Mazzo has an approval rating of 100% among the company's employees. This puts David J. Mazzo in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 53.0% of employees surveyed would recommend working at Caladrius Biosciences to a friend.
What other stocks do shareholders of Caladrius Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Caladrius Biosciences investors own include Brainstorm Cell Therapeutics (BCLI), HubSpot (HUBS), Karyopharm Therapeutics (KPTI), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Energy Transfer (ET), Inovio Pharmaceuticals (INO), AcelRx Pharmaceuticals (ACRX) and CTI BioPharma (CTIC).

This page (NASDAQ:CLBS) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Caladrius Biosciences Stock Price, News & Analysis (NASDAQ:CLBS)

About Caladrius Biosciences Stock (NASDAQ:CLBS)

CLBS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

CLBS Stock Analysis - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info